Tomahawk, WI 03/06/2014 (Basicsmedia) – Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is seeking to replicate the success of EXPAREL and wants to expand its usage. The company will be presenting data about the results obtained through use of EXPAREL at the 81st annual meeting of the American Academy of Orthopedic Surgeons (AAOS).

The EXPAREL experience:

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)’s EXPAREL has been developed to manage post surgical pain following knee and hip replacement. The drug is administered as a single dose into the surgical site to reduce the pain felt after the surgery; it produces post surgical analgesia. It was commercially launched in the U.S. in 2012 and uses the company’s proprietary product delivery technology called ‘DepoFoam’. This allows for a small quantity of the drug to be released for a prolonged period of time. Buoyed by its success, the company is looking at other uses of the technology as it seeks to expand the usage of the drug. There are several surgeries which require pain management for some time after the surgeries are completed.

Financial results disappoint:

Though this news will gladden the hearts of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)’s investors, they were disappointed by the results declared recently. The company reported an increase in revenues by 22% to $33.6 million on y-on-y basis. Analaysts were expecting revenues of $31 million for the fourth quarter. Hoever, earnings took a dive as the company reported a net loss of $0.36 per share for the fourth quarter. It was wider than that expected by the analysts. They had forecasted that the company would lose $0.31 per share. However the company managed to narrow down the losses on a y-on-y basis, it had declared a loss of $0.5 per share for the same period last year. EXPAREL contributed $30.5 to the revenues, the sales was higher by more than 52% sequentially.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is expected to submit a sNDA (supplementary New Drug Application) to the FDA for femoral nerve block in total knee replacement. It has already submitted a Prior Approval Supplement (PAS) for an additional manufacturing site.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.